Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278

CORK, Ireland, September 3, 2010 - Tibotec Pharmaceuticals today announced its submission of a Marketing
Authorisation Application (MAA) to the European Medicines Agency (EMA) for
TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside
reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. The
proposed indication would make TMC278 available for once-daily use with other
antiretroviral agents in treatment-naïve HIV-1-infected adults.

It is estimated that 33.4 million people are living with HIV
worldwide,[1] 2.3 million of which are in Europe.[2] Research shows that
antiretrovirals have helped to extend life expectancy for people living with
HIV.[3] However, new treatments are needed which suppress the replication of
the virus while also minimizing the occurrence of unwanted side effects.[4]

The TMC278 filing is based on an extensive global clinical development
programme involving more than 1,350 patients[5] in over 20 countries. If
approved, TMC278 would help to expand the treatment options for people living
with HIV.

"Thanks to advances in treatment, people with HIV are living longer than
ever before, which is made possible by continuous research for new and
improved treatments," said Eric Lefebvre, Medical Director at Tibotec. "The
EMA regulatory submission for TMC278 represents an important part of our
ongoing commitment to HIV and to helping patients receive the treatment and
care they need."

Pending EMA approval, Tibotec will commercialize TMC278 in the European
Union. Tibotec has also submitted new drug applications in the US and Canada,
and regulatory submissions for TMC278 in other countries are expected in the
coming months. Tibotec has entered into a license and collaboration agreement
with Gilead Sciences, Inc. (Nasdaq: GILD) for the development and
commercialization of a once-daily fixed-dose combination of TMC278 and
Gilead's Truvada(R) (emtricitabine and tenofovir disoproxil (as fumarate)).

About TMC278

TMC278 is an investigational NNRTI, which blocks the reverse
transcriptase, a key enzyme the HIV virus uses to replicate. The regulatory
application for TMC278 is based on the 48-week results of two pivotal Phase 3
double-blind, randomized studies recently presented at the International AIDS
Congress, known as ECHO (TMC278-TiDP6-C209) and THRIVE (TMC278-TiDP6-C215).5
The studies evaluated the efficacy, safety and tolerability of once-daily
TMC278, in combination with two NRTIs, in treatment-naïve HIV-1-infected
adults, and both reached their primary objective of demonstrating
non-inferiority of TMC278 vs. efavirenz in the percentage of patients
achieving an undetectable viral load (less than 50 copies/mL) at week 48
(with a maximum allowable difference of 12 percent).5 The studies showed that
TMC278 demonstrated significant improvements in tolerability, with lower
rates of discontinuations due to adverse events including dizziness, abnormal
dreams and nightmares, and rashes.5

About Tibotec Pharmaceuticals

Tibotec Pharmaceuticals, based in Cork, Ireland, is a pharmaceutical
research and development company. The Company's main research and development
facilities are in Beerse, Belgium, with offices in Titusville, NJ, USA.
Tibotec is dedicated to the discovery and development of innovative HIV/AIDS
drugs and anti-infectives for diseases of high unmet medical need.

About Tibotec, a division of Janssen-Cilag

Tibotec, a division of Janssen-Cilag, brings innovative products for
HIV/AIDS to patients in Europe, the Middle East and Africa focusing on
patients' and healthcare providers' specific needs in this disease domain.
The company will also commercialise medicines to combat other viral diseases
in the future.

About Janssen-Cilag

Janssen-Cilag is a leader in traditional and biological medicines in
areas such as gastroenterology, women's health, mental health and neurology
as well as for pain, oncology, haematology and nephrology.

Tibotec Pharmaceuticals and Janssen-Cilag are subsidiaries of the Johnson
& Johnson family of companies.

Truvada is a registered trademark of Gilead Sciences, Inc.

References

———————————

[1] World Health Organization: HIV Global epidemic data and statistics.
Available at: www.who.int/hiv/data/global_data/en/index.html Last
accessed: August 2010

[2] Avert: European HIV and AIDS Statistics. Available at:
www.avert.org/hiv-aids-europe.htm Last accessed: August 2010

[3] Lewden C. Responders to antiretroviral treatment over 500 CD4/mm3
reach same mortality rates as general population: APROCO and Aquitaine
Cohorts. 10th European AIDS Conference abstract. 2005. PE18.4/8.

[4] HIV/AIDS Outlook: The Outlook for a Cure. Available at:
virginiahughes.com/2010/07/20/hiv-outlook-for-a-cure/ Last accessed:
August 2010

[5] Cohen C et al. Pooled Week 48 efficacy and safety results from ECHO
andTHRIVE, two double-blind, randomised, Phase III trials comparing TMC278
versus efavirenz in treatment-naive, HIV-1-infected patients. IAC abstract.
2010.

Media Contact: Hans Vanavermaete, Mobile: +32-478-44-72-78